ERBB2 and breast carcinoma: In the last two decades, various mAbs have been approved by FDA for the treatment of cancers such as Rituximab (anti‐CD20), Daratumumab (anti‐CD38) cetuximab (anti‐EGFR), trastuzumab (anti‐HER2) and bevacizumab (anti‐VEGF‐A/anti‐angiogenic) for the treatment of lymphoma, multiple myeloma, epithelial cancer, HER2‐positive breast cancer, respectively.32, 156, 157